HOLON, Israel, July 24, 2017 /PRNewswire/ --
Compugen Ltd. (NASDAQ: CGEN), a therapeutic discovery company,
announced today that the Company will release its second quarter
financial results on Wednesday, August 2,
2017 before the U.S. financial markets open. Management will
host a live webcast to review the results and provide a corporate
update at 10:00 AM ET.
To access the live conference call by telephone, please dial
1-888-668-9141 from the US, or +972-3-918-0609 internationally. The
call will also be available via live webcast through Compugen's
website, located at the following link. Following the live audio
webcast, a replay will be available on the Company's website.
About Compugen
Compugen is a leading therapeutic discovery company whose
mission is to utilize its broadly applicable predictive discovery
infrastructure to discover novel drug targets and develop
first-in-class therapeutics. Our current pipeline consists of early
and preclinical stage immuno-oncology programs based on novel drug
targets discovered internally, primarily immune checkpoint and
myeloid protein target candidates. These programs focus on the
development of first-in-class cancer immunotherapy drugs with the
potential to harness the immune system to provide treatment
solutions in areas of unmet medical need in various cancer types
and patient populations, both as monotherapy and in combination
with other drugs. In addition, our pipeline currently includes a
preclinical fusion protein autoimmune product candidate. Compugen's
business model is based on selectively entering into collaborations
for its novel target candidates and related drug product candidates
at various stages of research and development under revenue-sharing
agreements. The Company is headquartered in Israel, with R&D facilities in
Israel and South San Francisco. At
the US facilities, therapeutic monoclonal antibodies are discovered
and developed against the Company's novel drug target candidates.
For additional information, please visit Compugen's corporate
website at http://www.cgen.com.
Company contact:
Elana Holzman
Director, Investor Relations and Corporate Communications
Compugen Ltd.
Email: elanah@cgen.com
Tel: +972(3)765-8124
SOURCE Compugen Ltd.